Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Durvalumab + Cediranib in Metastatic Uveal Melanoma
2019-001045-40Phase 2Active
- Sponsor
- Gem
- Start
- Jan 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and cediranib in intraocular melanoma, sponsored by Gem. Primary endpoint: Objective response rate. Started Jan 2020; status: active.
02
Drugs
durvalumabcediranib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2019-001045-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001045-40.